{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-24-000125","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.849441+00:00","generated_at":"2026-05-31T07:33:31.566837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lifecore reports FY 2024 revenue $128.3M (+24.2%), Adj. EBITDA $20.2M; FY25 rev guidance $126.5-130M","bullets":["FY 2024 revenue $128.3M (+24.2% YoY); Q4 revenue $37.9M (+21.6% YoY).","FY 2024 net income $9.3M (incl. $39.5M non-cash gain) vs loss $64.2M; Adj. EBITDA $20.2M.","Q4 net loss $7.1M vs $37.0M (prior yr had $23.7M debt extinguish loss); Adj. EBITDA $10.4M.","FY 2025 guidance: rev $126.5-130M, Adj. EBITDA $19-21M, capex $10-14M.","5-head isolator filler GMP-ready Sept 2024; headcount reduced in July; SEC filings current."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-24-000125","json":"https://secwatch.observer/filing/0001005286-24-000125.json","markdown":"https://secwatch.observer/filing/0001005286-24-000125.md","text":"https://secwatch.observer/filing/0001005286-24-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000125/0001005286-24-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000125/lndc-20240826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:33:31.566837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}